Recombinant Human VPAC2 Protein (Fc Tag)
Beta LifeScience
SKU/CAT #: BLPSN-4836
Recombinant Human VPAC2 Protein (Fc Tag)
Beta LifeScience
SKU/CAT #: BLPSN-4836
Collections: Other recombinant proteins, Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Tag | Fc |
Host Species | Human |
Accession | NP_003373.2 |
Synonym | C16DUPq36.3, DUP7q36.3, PACAP-R-3, PACAP-R3, VIP-R-2, VPAC2, VPAC2R, VPCAP2R |
Background | VIP and PACAP receptor 2, or VIPR2 encodes the VPAC2 receptor, which binds both VIP and PACAP. VPAC2 is expressed throughout the central nervous system and the periphery. Mutations in the VIPR2 homolog in the mouse cause hypoactivity, as well as disruptions in circadian rhythm. Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. |
Description | A DNA sequence encoding the human VIPR2 (NP_003373.2) (Met1-Val126) was expressed with the Fc region of mouse IgG1 at the C-terminus. |
Source | HEK293 |
Predicted N Terminal | Glu 24 |
AA Sequence | Met1-Val126 |
Molecular Weight | The recombinant human VIPR2/mFc comprises 337 a.a. and has a predicted molecular mass of 38.1 kDa. The apparent molecular mass of the monomer is approximately 50.6 kDa in SDS-PAGE under reducing conditions. |
Purity | >90% as determined by SDS-PAGE |
Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method |
Bioactivity | Please contact us for detailed information |
Formulation | Lyophilized from sterile PBS, pH 7.4.. |
Stability | The recombinant proteins are stable for up to 1 year from date of receipt at -70°C. |
Usage | For Research Use Only |
Storage | Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |